Using a previously developed in vitro model to characterize the enterocyte‐adherent microbiota fraction, we explored the potential of the probiotic strain Bifidobacterium animalis ssp. lactis BI07 to modulate the inflammation‐dependent dysbioses of the enterocyte‐adherent microbiota from 12 healthy human donors. According to our findings, B. animalis ssp. lactis BI07 is effective in limiting the increase of pro‐inflammatory pathobionts on the inflamed mucosal site, supporting the recovery of a mutualistic community. Bifidobacterium animalis subsp. lactis BI07, a well‐known probiotic strain, has shown the potential to redress inflammation‐dependent dysbioses of the enterocyte adherent fraction of the human intestinal microbiota.